schizandrin has been researched along with ginsenosides in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| He, J; Liu, Y; Sha, D; Wang, L; Zheng, S | 1 |
| Yan, YQ; Yu, BY; Yue, L; Zhu, DN | 1 |
| Fan, XH; Guo, WJ; Shao, Q; Zhang, YF | 1 |
| Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S | 1 |
| Cao, G; Cao, Z; Guo, Z; Kou, J; Li, L; Yang, H; Yu, B; Zhou, H | 1 |
| Jiang, M; Kang, L; Li, Z; Liu, X; Wang, Y; Xu, L; Zhao, X | 1 |
| Chen, HL; Kou, JP; Li, DP; Li, F; Tan, YS; Yan, Y; Yu, BY; Zhai, KF | 1 |
| Chen, HL; Kou, JP; Li, F; Lv, YN; Shen, K; Tan, YS; Yu, BY; Zhai, KF | 1 |
| Fan, X; Kou, J; Li, F; Ma, X; Pang, L; Song, M; Yu, B; Zhang, Y | 1 |
| Chu, C; Fan, XX; Kou, JP; Li, F; Yu, BY; Zhang, Y | 1 |
| Kong, L; Sun, H; Wang, XJ; Wang, XQ; Yu, JB; Zhang, AH; Zhang, QY | 1 |
| Kou, J; Lai, Q; Li, F; Yang, W; Yu, B; Zhang, L; Zhang, Y | 1 |
| Hu, H; Li, Y; Wang, Z; Xu, C; Yang, K; You, Y; Zhao, L; Zhou, W | 1 |
13 other study(ies) available for schizandrin and ginsenosides
| Article | Year |
|---|---|
[Thin layer chromatographic studies on radix Ginseng, fructus Schisandrae and radix Salviae miltiorrhizae in yixinfumai granules].
Topics: Chromatography, Thin Layer; Cyclooctanes; Dioxoles; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Lignans; Panax; Plants, Medicinal; Polycyclic Compounds; Saponins | 1992 |
[Relationship between components changes and efficacy of Shengmaisan VII. Chemical dynamic change of schisandrin in Shengmaisan].
Topics: Cyclooctanes; Drug Combinations; Drug Interactions; Drugs, Chinese Herbal; Ginsenosides; Lignans; Ophiopogon; Panax; Plants, Medicinal; Polycyclic Compounds; Schisandra | 2006 |
[Pharmacokinetics interaction among three major active compounds of Shengmai formula in rats].
Topics: Animals; Biological Availability; Chromatography, Liquid; Cyclooctanes; Drug Synergism; Ginsenosides; Lignans; Male; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2012 |
A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Topics: Administration, Intravenous; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Cyclooctanes; Drug Interactions; Drug Synergism; Ginsenosides; Half-Life; Lignans; Male; Medicine, Chinese Traditional; Models, Biological; Nitric Oxide; Panax; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Schisandra | 2014 |
A combination of four active compounds alleviates cerebral ischemia-reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways.
Topics: Adenine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autophagy; Brain; Brain Infarction; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Infarction, Middle Cerebral Artery; Lignans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Polycyclic Compounds; Renal Circulation; Reperfusion Injury; Saponins; Time Factors; TOR Serine-Threonine Kinases | 2014 |
A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats.
Topics: Animals; Cyclooctanes; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Lignans; Magnetic Resonance Spectroscopy; Male; Metabolome; Metabolomics; Myocardial Infarction; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Saponins; Spirostans | 2014 |
Identification of schisandrin as a vascular endothelium protective component in YiQiFuMai Powder Injection using HUVECs binding and HPLC-DAD-Q-TOF-MS/MS analysis.
Topics: Apoptosis; Cardiovascular Agents; Cell Hypoxia; Cell Survival; Chromatography, High Pressure Liquid; Cyclooctanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Ginsenosides; Human Umbilical Vein Endothelial Cells; Humans; L-Lactate Dehydrogenase; Lignans; Malondialdehyde; Nitric Oxide; Polycyclic Compounds; Reactive Oxygen Species; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2015 |
An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases.
Topics: Animals; Brain Ischemia; Cell Line; Cyclooctanes; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Humans; Lignans; Myocardial Ischemia; NF-kappa B; Oxidative Stress; PC12 Cells; Polycyclic Compounds; Protein Interaction Maps; Rats; Saponins; Signal Transduction; Systems Biology; Tumor Necrosis Factor-alpha | 2015 |
Cardioprotection by combination of three compounds from ShengMai preparations in mice with myocardial ischemia/reperfusion injury through AMPK activation-mediated mitochondrial fission.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; Cyclooctanes; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Dynamins; Ginsenosides; Lignans; Male; Mice, Inbred ICR; Mitochondrial Dynamics; Myocardial Reperfusion Injury; Polycyclic Compounds; Spirostans | 2016 |
A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia.
Topics: Animals; Creatine Kinase, MB Form; Cyclooctanes; Disease Models, Animal; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Heart; Isoproterenol; L-Lactate Dehydrogenase; Lignans; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pituitary Hormones, Posterior; Polycyclic Compounds; Spirostans; Troponin I | 2018 |
Identifying quality-markers from Shengmai San protects against transgenic mouse model of Alzheimer's disease using chinmedomics approach.
Topics: Alzheimer Disease; Animals; Biomarkers, Pharmacological; Cyclooctanes; Dioxoles; Disease Models, Animal; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Lignans; Male; Medicine, Chinese Traditional; Metabolomics; Mice, Transgenic; Neuroprotective Agents; Polycyclic Compounds | 2018 |
Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury.
Topics: Animals; Cell Line; Cell Survival; Cyclooctanes; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Inflammation Mediators; Lignans; Male; Mice; Mice, Inbred ICR; Myocardial Reperfusion Injury; Myocytes, Cardiac; Polycyclic Compounds; Rats; Spirostans; Treatment Outcome | 2021 |
Effects of schisandra lignans on the absorption of protopanaxadiol-type ginsenosides mediated by P-glycoprotein and protopanaxatriol-type ginsenosides mediated by CYP3A4.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Ginsenosides; Lignans; Molecular Docking Simulation; Plant Extracts; Schisandra | 2024 |